https://www.selleckchem.com/products/mi-503.html
n terms of antiviral effectiveness in patients with mild to moderate COVID-19. Furthermore, the combination of RBV and LPV/r is associated with a significant increase in gastrointestinal adverse events, suggesting that RBV and LPV/r should not be co-administered to COVID-19 patients simultaneously. www.ClinicalTrials.gov, ID ChiCTR2000029387. Registered on January 28, 2019. www.ClinicalTrials.gov, ID ChiCTR2000029387. Registered on January 28, 2019.Taoren Honghua drug is a traditional Chinese medicinal drug used to treat cardiovascular d
Like
Comment
Share
